abc biopply Organoid Competence Centers
abc biopply AG provides validated highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis humanized multi-organoid technology™ on clinically relevant disease models (e.g. oncology, neurology, hepatic, obesity etc.)
In addition, the technology allows us to custom tailor or design any disease model and than license it to our clients for in-house implementation and scale up.
Highlights of our Integrated Organoid Services:
- Preclinical assays: drug efficacy, safety, toxicology, IC50, dose response, relapse and resistance studies
- Disease models: oncology, neurology, hepatic, renal, and cartilage
- Custom-tailored model development and biomarker discovery
- Integrated preclinical services, from in vitro to in vivo, synchronized with humanized mouse models via our partner Preclina
Together, these offerings enable faster, more reliable drug discovery while reducing reliance on animal testing.
3D CoSeedis - Innovative technology for humanized multi-organoid models
abc biopply AG is a Swiss SME pioneering humanized 3D multi-organoid models that boost drug discovery and development from in vitro to ex vivo. Our proprietary 3D CoSeedis multi-organoid in chip technology™ delivers highly predictive, scalable, and standardized preclinical models validated in oncology, neurology, immunology, and safety testing. With proven scientific publications, strong IP, and strategic partnerships, we provide integrated preclinical services and flexible licensing options that reduce reliance on animal models and accelerate the path to clinic.
abc biopply provides humanized 3D CoSeedis multi-organoid disease models™ that deliver superior predictiveness and scalability compared to conventional in vitro systems.
Innovation Highlights:
- Proprietary permeable matrix composition and design
- Intrinsic self-organization of physiological microenvironments
- Different formats with up to 1000 replicates
- 98.2% uniformity and homogeneity of organoids
- Full scalability of complex models (break of easy-many vs complex –few rule)
- 360degree nutrition supply prevents partial starvation as in conventional 3D systems
- Allow to mimic specific organs and tissues in culture over long periods of time
- Documented with over 20 recognized scientific publications
- Protected by multiple IP covering EU and US
abc biopply - Opening new horizons in humanizing preclinical multi-organoid disease models
We free preclinical models from non-human components whenever possible.
Conventional cellular or animal disease models have shown that the predictability of patient response to treatment is severely limited. Great efforts have been made to humanize mouse models to better predict certain aspects of human physiology and immunology. The abc biopply team has made a significant breakthrough in humanizing upstream 3D cell models through the revolutionary and proprietary3D CoSeedis multi-organoid in chip technology™. Thanks to exceptional physiological growth conditions and unique ways of intercellular communication, our models are free from non-human components to the greatest extent possible and allow us to mimic specific organs and tissues in culture over long periods of time. Thus, we successfully bridge the translational gap with unparalleled physiological responses and unique statistical predictive power.
Services
abc biopply offers a comprehensive portfolio of validated service packages based on the proprietary 3D CoSeedis multi-organoid in chip technology™.
